The optimal definition and prediction nomogram for left ventricular remodelling after acute myocardial infarction.
Acute myocardial infarction
Definition
Left ventricular remodelling
Percutaneous coronary intervention
Prediction nomogram
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
20
06
2023
received:
13
03
2023
accepted:
04
07
2023
medline:
13
10
2023
pubmed:
25
7
2023
entrez:
25
7
2023
Statut:
ppublish
Résumé
Left ventricular (LV) remodelling after acute myocardial infarction (AMI) is associated with heart failure and increased mortality. There was no consensus on the definition of LV remodelling, and the prognostic value of LV remodelling with different definitions has not been compared. We aimed to find the optimal definition and develop a prediction nomogram as well as online calculator that can identify patients at risk of LV remodelling. This prospective, observational study included 829 AMI patients undergoing percutaneous coronary intervention from January 2015 to January 2020. Echocardiography was performed within the 48 h of admission and at 6 months after infarction to evaluate LV remodelling, defined as a 20% increase in LV end-diastolic volume (LVEDV), a 15% increase in LV end-systolic volume (LVESV), or LV ejection fraction (LVEF) < 50% at 6 months. The impact of LV remodelling on long-term outcomes was analysed. Lasso regression was performed to screen potential predictors, and multivariable logistic regression analysis was conducted to establish the prediction nomogram. The area under the curve, calibration curve and decision curve analyses were used to determine the discrimination, calibration and clinical usefulness of the remodelling nomogram. The incidences of LV remodelling defined by LVEDV, LVESV and LVEF were 24.85% (n = 206), 28.71% (n = 238) and 14.60% (n = 121), respectively. Multivariable Cox regression models demonstrated that different definitions of LV remodelling were independently associated with the composite endpoint. However, only remodelling defined by LVEF was significantly connected with long-term mortality (hazard ratio = 2.78, 95% confidence interval 1.41-5.48, P = 0.003). Seven variables were selected to construct the remodelling nomogram, including diastolic blood pressure, heart rate, AMI type, stent length, N-terminal pro brain natriuretic peptide, troponin I, and glucose. The prediction model had an area under the receiver operating characteristics curve of 0.766. The calibration curve and decision curve analysis indicated consistency and better net benefit in the prediction model. LV remodelling defined by LVEDV, LVESV and LVEF were independent predictors for long-term mortality or heart failure hospitalization in AMI patients after percutaneous coronary intervention. However, only remodelling defined by LVEF was suitable for predicting all-cause death. In addition, the nomogram can provide an accurate and effective tool for the prediction of postinfarct remodelling.
Identifiants
pubmed: 37489064
doi: 10.1002/ehf2.14479
pmc: PMC10567660
doi:
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2955-2965Informations de copyright
© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Eur Heart J. 2011 Jul;32(13):1640-8
pubmed: 21398642
Circ Cardiovasc Imaging. 2020 Jul;13(7):e009937
pubmed: 32689822
Am J Cardiol. 1975 Jan;35(1):30-6
pubmed: 1109244
Arq Bras Cardiol. 2020 Apr;114(4):666-672
pubmed: 32074200
PLoS One. 2016 Dec 29;11(12):e0168109
pubmed: 28033331
Eur Heart J. 2018 Jun 21;39(24):2255-2262
pubmed: 29394350
J Pharmacol Exp Ther. 2004 Jan;308(1):236-40
pubmed: 14569053
Circulation. 2003 May 27;107(20):2577-82
pubmed: 12732606
Circulation. 2005 May 31;111(21):2837-49
pubmed: 15927992
J Am Coll Cardiol. 2010 Dec 7;56(24):1973-83
pubmed: 21126638
Stat Med. 2007 Dec 30;26(30):5512-28
pubmed: 18058845
Circ Res. 1962 May;10:798-806
pubmed: 14036322
JACC Heart Fail. 2020 Feb;8(2):131-140
pubmed: 31838030
Heart. 2018 Jul;104(14):1156-1164
pubmed: 29352006
J Cardiol. 2016 Sep;68(3):241-7
pubmed: 26527112
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Korean Circ J. 2011 Mar;41(3):124-9
pubmed: 21519510
Int J Cardiol. 2018 May 15;259:40-42
pubmed: 29486997
ESC Heart Fail. 2021 Aug;8(4):3014-3025
pubmed: 34002938
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Hypertension. 2005 Mar;45(3):412-8
pubmed: 15655115
Circulation. 1986 Oct;74(4):693-702
pubmed: 3757183
Eur Heart J Cardiovasc Imaging. 2012 Nov;13(11):948-53
pubmed: 22531464
J Am Coll Cardiol. 2016 May 3;67(17):2050-60
pubmed: 27126533
JACC Heart Fail. 2017 Nov;5(11):772-781
pubmed: 29096787
JACC Heart Fail. 2016 Apr;4(4):237-48
pubmed: 26682794
Int J Mol Sci. 2019 Apr 12;20(8):
pubmed: 31013779
ESC Heart Fail. 2023 Oct;10(5):2955-2965
pubmed: 37489064
J Am Coll Cardiol. 2000 Mar 1;35(3):569-82
pubmed: 10716457
Circulation. 1994 Jan;89(1):68-75
pubmed: 8281697
Int J Cardiol. 2016 Apr 15;209:17-9
pubmed: 26878466
Cardiovasc Diabetol. 2019 Aug 7;18(1):100
pubmed: 31391045
Circulation. 2002 Oct 29;106(18):2351-7
pubmed: 12403666
Am J Cardiol. 2014 Nov 15;114(10):1490-6
pubmed: 25248808
Circulation. 1997 Nov 18;96(10):3294-9
pubmed: 9396419
J Am Coll Cardiol. 2007 Oct 16;50(16):1532-40
pubmed: 17936151
Eur Cardiol. 2016 Aug;11(1):29-35
pubmed: 30310445
Br J Pharmacol. 2008 Apr;153(8):1589-601
pubmed: 18223669